News
SCNX
3.990
-3.39%
-0.140
Scienture Holdings Executes Reverse Stock Split to Retain Listing
TipRanks · 21h ago
Weekly Report: what happened at SCNX last week (0928-1002)?
Weekly Report · 3d ago
Upcoming Stock Splits This Week (October 5–9) – Stay Invested
TipRanks · 4d ago
Analyst Maintains Buy Rating on Scienture, Keeps 12-Month Price Target Unchanged at $1.50 on Strength of Arbli Commercial Progress
TipRanks · 5d ago
Scienture Holdings Inc trading halted, news pending
TipRanks · 5d ago
Scienture’s Arbli added to formularies at 3 U.S. pediatric academic med centers
TipRanks · 6d ago
EXCLUSIVE: Scienture Expands Institutional Reach for Hypertension Drug with New Hospital Adoptions
Benzinga · 6d ago
SCIENTURE Announces Arbli™ Added to Formularies at Three Leading U.S. Pediatric Academic Medical Centers and Hospitals
Barchart · 6d ago
Why Vicor Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Benzinga · 10/01 08:31
Scienture Holdings (SCNX) Stock Drops 19% After Hours: Here's What Happened
Benzinga · 10/01 05:57
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 09/30 21:05
Scienture announces reverse stock split
TipRanks · 09/30 20:10
Scienture Holdings, Inc. Announces Reverse Stock Split
Barchart · 09/30 15:05
Weekly Report: what happened at SCNX last week (0921-0925)?
Weekly Report · 09/28 09:31
Scienture Expands REZENOPY Reach To Addiction Centers Under Distribution Deal
NASDAQ · 09/22 13:26
Scienture expands commercial reach of Rexenopy to Addiction Treatment Centers
TipRanks · 09/22 12:25
SCIENTURE To Provide REZENOPY To Addiction Treatment Centers
Benzinga · 09/22 12:16
Weekly Report: what happened at SCNX last week (0914-0918)?
Weekly Report · 09/21 09:31
Scienture Holdings Updates Investor Presentation and Guidance
TipRanks · 09/14 20:33
Weekly Report: what happened at SCNX last week (0907-0911)?
Weekly Report · 09/14 09:33
More
Webull provides a variety of real-time SCNX stock news. You can receive the latest news about Scienture Holdings, Inc through multiple platforms. This information may help you make smarter investment decisions.
About SCNX
Scienture Holdings, Inc., through its wholly owned subsidiary, Scienture, LLC, is a specialty pharmaceutical company focused on providing enhanced value to patients, physicians and caregivers by offering specialty products to satisfy unmet market needs. Scienture, LLC is focused on developing and commercializing products for the treatment of central nervous system and cardiovascular diseases. Scienture LLC is developing a range of product candidates, including new potential treatments for hypertension, migraine, pain and thrombosis and other related disorders. The Company's product candidates include SCN- 102 (hypertension), SCN- 104 (CNS-Pain), SCN- 106 (Cardiovascular) and SCN- 107 (Pain). SCN-102 is an oral liquid formulation of losartan potassium in development for the treatment of hypertension. SCN-104 is a multi-dose pen-based delivery system for self-injection and increased patient convenience, which is in development for the acute treatment of migraine headaches.